Loading
Instead of paying hundreds of thousands up front for a CAR-T or gene therapy, the health system would pay in yearly instalments that stop if the cancer comes back, so companies are paid for cures, not attempts.
Outcome-based annuities, already used for some gene therapies (for example spinal muscular atrophy and haemophilia contracts in Europe), applied systematically to cell therapies, bispecifics with curative potential and future one-time oncology treatments: payment spread over five years, each instalment contingent on the patient remaining in remission by pre-agreed criteria (imaging, MRD negativity). Payers gain risk-sharing; manufacturers gain higher total payment for real cures and a strong incentive to select patients well and improve durability. Needs a registry to adjudicate outcomes and accounting rules that let payers commit across years.
Shares Ciltacabtagene autoleucel, Axicabtagene ciloleucel, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Ciltacabtagene autoleucel, Axicabtagene ciloleucel, Prices and value, CAR-T cell therapy.
Shares Ciltacabtagene autoleucel, Axicabtagene ciloleucel, CAR-T cell therapy.
Shares Launch prices indexed to the ESMO benefit scale, revisited when survival matures, Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares Ciltacabtagene autoleucel, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy, Multiple myeloma.
Shares Hospital-based CAR-T manufacturing at cost through a public network, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.